-
1
-
-
9244222261
-
Targeted cancer therapy
-
Sawyers C. Targeted cancer therapy. Nature. 2004;432:294-297.
-
(2004)
Nature
, vol.432
, pp. 294-297
-
-
Sawyers, C.1
-
2
-
-
33747855481
-
Comparing antibody and small-molecule therapies for cancer
-
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714-727.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 714-727
-
-
Imai, K.1
Takaoka, A.2
-
3
-
-
47249105667
-
Erlotinib: An EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
-
Schettino C, Bareschino MA, Ricci V, et al. Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expert Rev Respir Med. 2008;2:167-178.
-
(2008)
Expert Rev Respir Med
, vol.2
, pp. 167-178
-
-
Schettino, C.1
Bareschino, M.A.2
Ricci, V.3
-
4
-
-
34247224987
-
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study
-
Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8:387-394.
-
(2007)
Lancet Oncol
, vol.8
, pp. 387-394
-
-
Tejpar, S.1
Piessevaux, H.2
Claes, K.3
-
5
-
-
84858695125
-
Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: Systematic review and pooled analysis of randomized studies
-
Petrelli F, Borgonovo K, Cabiddu M, et al. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf. 2012;11:S9-S19.
-
(2012)
Expert Opin Drug Saf
, vol.11
, pp. S9-S19
-
-
Petrelli, F.1
Borgonovo, K.2
Cabiddu, M.3
-
6
-
-
79954586068
-
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
-
Janjigian YY, Azzoli CG, Krug LM, et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res. 2011;17:2521-2527.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2521-2527
-
-
Janjigian, Y.Y.1
Azzoli, C.G.2
Krug, L.M.3
-
7
-
-
77955640313
-
Effects of the EGFR inhibitor erlotinib on magnesium handling
-
Dimke H, van der Wijst J, Alexander TR, et al. Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol. 2010;21: 1309-1316.
-
(2010)
J Am Soc Nephrol
, vol.21
, pp. 1309-1316
-
-
Dimke, H.1
Van Der Wijst, J.2
Alexander, T.R.3
-
8
-
-
84891360060
-
EGFR inhibition induces proinflammatory cytokines via Nox4 HNSCC
-
Fletcher EV, Love-Homan L, Sobhakumari A, et al. EGFR inhibition induces proinflammatory cytokines via Nox4 HNSCC. Mol Cancer Res. 2013;11:1574-1584.
-
(2013)
Mol Cancer Res
, vol.11
, pp. 1574-1584
-
-
Fletcher, E.V.1
Love-Homan, L.2
Sobhakumari, A.3
-
9
-
-
79957886927
-
Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4
-
Orcutt KP, Parsons AD, Sibenaller ZA, et al. Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer Res. 2011;71:3932-3940.
-
(2011)
Cancer Res
, vol.71
, pp. 3932-3940
-
-
Orcutt, K.P.1
Parsons, A.D.2
Sibenaller, Z.A.3
-
10
-
-
84868119568
-
Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: Approaches to narrow the gaps between preclinical safety evaluation and clinical outcome
-
Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. J Appl Toxicol. 2012;32:945-951.
-
(2012)
J Appl Toxicol
, vol.32
, pp. 945-951
-
-
Yang, B.1
Papoian, T.2
-
11
-
-
84884134230
-
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes
-
Doherty KR, Wappel RL, Talbert DR, et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013;272:245-255.
-
(2013)
Toxicol Appl Pharmacol
, vol.272
, pp. 245-255
-
-
Doherty, K.R.1
Wappel, R.L.2
Talbert, D.R.3
-
12
-
-
84864200196
-
The EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction
-
Weglicki WB, Kramer JH, Spurney CF, et al. the EGFR tyrosine kinase inhibitor tyrphostin AG-1478 causes hypomagnesemia and cardiac dysfunction. Can J Physiol Pharmacol. 2012;90:1145-1149.
-
(2012)
Can J Physiol Pharmacol
, vol.90
, pp. 1145-1149
-
-
Weglicki, W.B.1
Kramer, J.H.2
Spurney, C.F.3
-
13
-
-
84887577724
-
Mg-supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress and cardiac dysfunction in rats
-
Mak IT, Kramer JH, Chen X, et al. Mg-supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress and cardiac dysfunction in rats. Am J Physiol Regul Integr Comp Physiol. 2013;305:R1102-R1111.
-
(2013)
Am J Physiol Regul Integr Comp Physiol
, vol.305
, pp. R1102-R1111
-
-
Mak, I.T.1
Kramer, J.H.2
Chen, X.3
-
14
-
-
70349527600
-
Neutral endopeptidase inhibition enhances substance P mediated inflammation due to hypomagnesemia
-
Weglicki WB, Chmielinska JJ, Kramer JH, et al. Neutral endopeptidase inhibition enhances substance P mediated inflammation due to hypomagnesemia. Magnes Res. 2009;22:1-7.
-
(2009)
Magnes Res
, vol.22
, pp. 1-7
-
-
Weglicki, W.B.1
Chmielinska, J.J.2
Kramer, J.H.3
-
15
-
-
79251614627
-
The role of magnesium deficiency in cardiovascular and intestinal inflammation
-
Weglicki WB, Mak IT, Chmielinska JJ, et al. The role of magnesium deficiency in cardiovascular and intestinal inflammation. Magnes Res. 2012;23:S199-S206.
-
(2012)
Magnes Res
, vol.23
, pp. S199-S206
-
-
Weglicki, W.B.1
Mak, I.T.2
Chmielinska, J.J.3
-
16
-
-
77449157660
-
AZT-Induced cardiovascular toxicity-attenuation by Mg-supplementation
-
Mak IT, Chmielinska JJ, Kramer JH, et al. AZT-Induced cardiovascular toxicity-attenuation by Mg-supplementation. Cardiovasc Toxicol. 2009;9:78-85.
-
(2009)
Cardiovasc Toxicol
, vol.9
, pp. 78-85
-
-
Mak, I.T.1
Chmielinska, J.J.2
Kramer, J.H.3
-
17
-
-
68849118038
-
Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia
-
Kramer JH, Spurney C, Iantorno M, et al. Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia. Am J Med Scis. 2009;338: 22-27.
-
(2009)
Am J Med Scis
, vol.338
, pp. 22-27
-
-
Kramer, J.H.1
Spurney, C.2
Iantorno, M.3
-
18
-
-
80055108518
-
Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade
-
Mak IT, Chmielinska JJ, Kramer JH, et al. Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: protection by substance P receptor blockade. Exp Clin Cardiol. 2011;16:121-124.
-
(2011)
Exp Clin Cardiol
, vol.16
, pp. 121-124
-
-
Mak, I.T.1
Chmielinska, J.J.2
Kramer, J.H.3
-
19
-
-
0242405536
-
Suppression of neutrophil and endothelial activation by substance P receptor blockade in the Mg-deficient rat
-
Mak IT, Kramer JH, Weglicki WB. Suppression of neutrophil and endothelial activation by substance P receptor blockade in the Mg-deficient rat. Mag Res. 2003;16:91-97.
-
(2003)
Mag Res
, vol.16
, pp. 91-97
-
-
Mak, I.T.1
Kramer, J.H.2
Weglicki, W.B.3
-
20
-
-
84875972623
-
Cisplatininduced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice
-
Van Angelen AA, Glaudemans B, van der Kemp AW, et al. Cisplatininduced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice. Nephrol Dial Transplant. 2013;28:879-889.
-
(2013)
Nephrol Dial Transplant
, vol.28
, pp. 879-889
-
-
Van Angelen, A.A.1
Glaudemans, B.2
Kemp Van Der, A.W.3
-
21
-
-
84874096811
-
The TRPM6/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity
-
Ledeganck KJ, Boulet GA, Bogers JJ, et al. The TRPM6/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity. PLoS One. 2013;8:e57016.
-
(2013)
PLoS One
, vol.8
, pp. e57016
-
-
Ledeganck, K.J.1
Boulet, G.A.2
Bogers, J.J.3
-
25
-
-
77956194805
-
Methionine sulfoxide reductase B1 (MsrB1) recovers TRPM6 channel activity during oxidative stress
-
Cao G, Lee KP, van der Wijst J, et al. Methionine sulfoxide reductase B1 (MsrB1) recovers TRPM6 channel activity during oxidative stress. J Biol Chem. 2010;285:26081-26087.
-
(2010)
J Biol Chem
, vol.285
, pp. 26081-26087
-
-
Cao, G.1
Lee, K.P.2
Wijst Van Der, J.3
-
26
-
-
0026733499
-
Pathobiology of magnesium deficiency: A cytokine/neurogenic inflammation hypothesis
-
Weglicki WB, Phillips TM, Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol. 1992; 263:R734-R737.
-
(1992)
Am J Physiol
, vol.263
, pp. R734-R737
-
-
Weglicki, W.B.1
Phillips, T.M.2
-
27
-
-
0029989106
-
Role of free radicals and substance P in magnesium deficiency
-
Weglicki WB, Mak IT, Kramer JH, et al. Role of free radicals and substance P in magnesium deficiency. Cardiovasc Res. 1996;31:677-682.
-
(1996)
Cardiovasc Res
, vol.31
, pp. 677-682
-
-
Weglicki, W.B.1
Mak, I.T.2
Kramer, J.H.3
-
28
-
-
0037491368
-
Dietary Mg-intake influence circulating pro-inflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress
-
Kramer JH, Mak IT, Phillips TM, et al. Dietary Mg-intake influence circulating pro-inflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress. Exp Biol Med. 2003;228:665-673.
-
(2003)
Exp Biol Med
, vol.228
, pp. 665-673
-
-
Kramer, J.H.1
Mak, I.T.2
Phillips, T.M.3
-
29
-
-
0031301905
-
Human monocytes and macrophages express substance P and neurokinin-1 receptor
-
Ho WZ, Lai JP, Zhu XH, et al. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol. 1997;159: 5654-5660.
-
(1997)
J Immunol
, vol.159
, pp. 5654-5660
-
-
Ho, W.Z.1
Lai, J.P.2
Zhu, X.H.3
-
30
-
-
84979852034
-
Epidermal growth factor receptor-tyrosine kinase inhibition by erlotinib causes hypomagnesemia, oxidative stress and cardiac dysfunction (abstract)
-
Weglicki WB, Mak IT, Chmielinska JJ, et al. Epidermal growth factor receptor-tyrosine kinase inhibition by erlotinib causes hypomagnesemia, oxidative stress and cardiac dysfunction (abstract). FASEB J. 2013;27: 1128.
-
(2013)
FASEB J
, vol.27
, pp. 1128
-
-
Weglicki, W.B.1
Mak, I.T.2
Chmielinska, J.J.3
-
31
-
-
0030943255
-
NMDA-receptor regulation of substance P release from primary afferent nociceptors
-
Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature. 1997;386: 721-724.
-
(1997)
Nature
, vol.386
, pp. 721-724
-
-
Liu, H.1
Mantyh, P.W.2
Basbaum, A.I.3
-
32
-
-
0027872354
-
Molecular and functional diversity of the NMDA receptor channel
-
Mishina M, Mori H, Araki K, et al. Molecular and functional diversity of the NMDA receptor channel. Ann N Y Acad Sci. 1993;707:136-152.
-
(1993)
Ann N y Acad Sci
, vol.707
, pp. 136-152
-
-
Mishina, M.1
Mori, H.2
Araki, K.3
-
33
-
-
0027884870
-
Molecular characterization of NMDA and metabotropic glutamate receptors
-
Masu M, Nakajima Y, Moriyoshi K, et al. Molecular characterization of NMDA and metabotropic glutamate receptors. Ann N Y Acad Sci. 1993; 707:153-164.
-
(1993)
Ann N y Acad Sci
, vol.707
, pp. 153-164
-
-
Masu, M.1
Nakajima, Y.2
Moriyoshi, K.3
-
34
-
-
84886395013
-
Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension
-
Dehlin HM, Manteufel EJ, Monroe AL, et al. Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. Int J Cardiol. 2013;168:4643-4651.
-
(2013)
Int J Cardiol
, vol.168
, pp. 4643-4651
-
-
Dehlin, H.M.1
Manteufel, E.J.2
Monroe, A.L.3
-
35
-
-
77950042300
-
The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
-
Hasinoff BB. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol Appl Pharmacol. 2010;244:190-195.
-
(2010)
Toxicol Appl Pharmacol
, vol.244
, pp. 190-195
-
-
Hasinoff, B.B.1
-
36
-
-
84902445827
-
Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies
-
Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014;3:e000665.
-
(2014)
J Am Heart Assoc
, vol.3
, pp. e000665
-
-
Hahn, V.S.1
Lenihan, D.J.2
Ky, B.3
-
37
-
-
50949132320
-
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
-
Chen M, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;117:84-95.
-
(2008)
Circulation
, vol.117
, pp. 84-95
-
-
Chen, M.1
Kerkelä, R.2
Force, T.3
-
38
-
-
43549105662
-
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)
-
Metro G, Finocchiaro G, Toschi L, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials. 2006;1:1-13.
-
(2006)
Rev Recent Clin Trials
, vol.1
, pp. 1-13
-
-
Metro, G.1
Finocchiaro, G.2
Toschi, L.3
|